BIVDA Press Releases


UK Continues to Lag EU Market for In-Vitro Diagnostic Expenditure

The European IVD Market Statistics Report 2016 has been published by MedTech Europe and is available on their website1

Overall EU-27 + Turkey

The market continued to recover from the low of 2013 with growth overall of 1.1% (+€129m) but has still not yet surpassed 2011 revenues. Four out of five of the largest markets grew slightly in 2016 (Italy being the exception) but the principal contribution to growth was from new member states (+€76m, 8.1%). For the first time results for non-Euro countries were also reported in local currency. The headline figures above are calculated using constant exchange rates, so currency fluctuations are not considered in the overall market valuations. Technically a decline in the value of a local currency should be reflected in the market value in Euro for that country. The local currency data are included to allow calculation of these 'real' Euro values if desired.

UK Market

The UK IVD market, despite a relatively strong growth of 2.5%, remains at a low percentage of health care expenditure and a low per capita expenditure relative to other developed countries. Although ranking 2nd in GDP and GDP per capita (after Germany), the UK is 11th for total health care expenditure per capita, and 15th of the EU-15 for IVD expenditure per capita, ranking even below the Baltic States, the Czech Republic and Malta. Comparison with the other top three countries shows that only a little over half as much is spent per head on IVDs as in Germany and Italy. France reports only laboratory tests (so excluding e.g. glucose self-testing) but still reports 39% higher IVD per capita expenditure than the UK. Should any comparison with non-EU countries be sought, the values for Norway and Iceland are over twice that of the UK, and Switzerland over three times.

In the current NHS crisis situation it is hard to argue for greater expenditure on any element of health care provision except as part of overall greater provision. Nonetheless, as BIVDA argues, appropriate IVD expenditure can improve health care outcomes and decrease costs in many cases. That the UK lags so far behind comparable countries in its use of IVD solutions is a concern and a challenge to the Industry and to BIVDA, its representative body.



John Bagshaw is on the BIVDA Executive Board and chairs the Market Dynamics Working Party, representing BIVDA on the MedTech Europe Market Research Committee.

MedTech Europe is the trade association representing IVD and medical devices companies in Europe


European Parliament endorses new Regulation on In Vitro Diagnostics

The European Parliament has endorsed the new Regulation on In Vitro Diagnostics (IVDR), a developmen...

Read More >

BIVDA comment on Withdrawal Agreement and political declaration

Doris-Ann Williams, Chief Executive of BIVDA, comments on the announcement of the Withdrawal Agreeme...

Read More >

Government Responds to AAR Report – BIVDA’s View

The Government has today (04 November) published its response to the final report of the Accelerated...

Read More >

Autumn Statement 2016: BIVDA’s Response

Commenting on the 2016 Autumn Statement, BIVDA’s Chief Executive Doris-Ann Williams MBE said: “...

Read More >

BIVDA Launches Vision for Increasing Access to Molecular Diagnostics

A new report from the British In Vitro Diagnostics Association (BIVDA) has called for NHS England to...

Read More >

BIVDA’s Response to the 2017 General Election Result

Commenting on the result of the Election, BIVDA’s Chief Executive Doris-Ann Williams MBE said: “...

Read More >